Skip to main content

Hu Mei Mei's Form 4 filing

Vaxxinity, Inc. (VAXX) · filed Nov 15, 2021

Accession no.
0000899243-21-044643
Filed
Nov 15, 2021
Trade date
Nov 12-15, 2021
Filing delay
3 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market purchases total $241.8K. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Hu Mei MeiCIK 0001890585Director, Officer (See Remarks), 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 15, 2021Class A common stockCConversionAcquired+271,655–F1–271,655Indirect
Nov 15, 2021Class A common stockCConversionAcquired+247,050–F1–51,585,416Indirect
Nov 15, 2021Class A common stockCConversionAcquired+4,212,495–F1–4,212,495Indirect
Nov 12, 2021Class A common stockPPurchaseAcquired+17,500$13.82F5+$241,85017,500Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 15, 2021Class A common stockCConversionDisposed−271,655–F1–0Indirect
Nov 15, 2021Class A common stockCConversionDisposed−247,050–F1–0Indirect
Nov 15, 2021Class A common stockCConversionDisposed−4,212,495–F1–0Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Shares of preferred stock automatically converted into shares of Class A common stock upon closing of the Issuer's initial public offering based on a conversion rate of approximately 0.643 shares of Class A common stock for each share of preferred stock.

Referenced by the price of 3 transactions in Table I and 3 transactions in Table II.

F5

The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.56 to $13.95, inclusive.

Referenced by the price of 1 transaction in Table I.

Remarks

Chief Executive Officer and President. The Reporting Person, Louis Reese, Blackfoot and UBI have entered into a voting agreement providing the Reporting Person with the authority (and irrevocable proxies) to vote the shares of capital stock held by such stockholders at the Reporting Persons' discretion on all matters to be voted upon by stockholders of Vaxxinty, Inc. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by such stockholders in which the Reporting Person has no pecuniary interest.

Read the full filing on SEC EDGAR (opens in a new tab)